Evolent Health (EVH) Given Daily Media Sentiment Score of 0.21
News articles about Evolent Health (NYSE:EVH) have been trending somewhat positive on Wednesday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Evolent Health earned a news impact score of 0.21 on Accern’s scale. Accern also gave headlines about the technology company an impact score of 44.7592791329642 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Updates on Most Active Stock: Evolent Health Inc Class A Com (EVH) – ExpertGazette (expertgazette.com)
- Evolent Health, Inc (EVH) Upgraded by Zacks Investment Research to “Hold” (americanbankingnews.com)
- Analyzing Evolent Health (EVH) and The Competition (americanbankingnews.com)
- Analytics Reaffirm Evolent Health (EVH) Sell Recommendation – Investorplace.com (investorplace.com)
- Evolent Health, Inc (EVH) Receives Buy Rating from Canaccord Genuity (americanbankingnews.com)
Several analysts have recently commented on EVH shares. Jefferies Group LLC reissued a “buy” rating and issued a $28.00 price objective on shares of Evolent Health in a research note on Wednesday, September 6th. KeyCorp started coverage on Evolent Health in a research note on Tuesday, September 19th. They issued an “overweight” rating and a $23.00 price objective for the company. Robert W. Baird reissued an “outperform” rating and issued a $25.00 price objective (down from $35.00) on shares of Evolent Health in a research note on Tuesday, September 26th. They noted that the move was a valuation call. Cowen and Company reissued an “outperform” rating and issued a $35.00 price objective on shares of Evolent Health in a research note on Wednesday, June 28th. Finally, BidaskClub downgraded Evolent Health from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $28.45.
Evolent Health (NYSE EVH) traded up 0.30% during trading on Wednesday, hitting $16.65. The stock had a trading volume of 1,230,360 shares. Evolent Health has a 1-year low of $14.50 and a 1-year high of $27.50. The company’s market capitalization is $1.10 billion. The stock’s 50-day moving average price is $17.39 and its 200-day moving average price is $17.39.
Evolent Health (NYSE:EVH) last released its earnings results on Monday, August 7th. The technology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The firm had revenue of $107.30 million during the quarter, compared to analyst estimates of $104.45 million. During the same period last year, the business earned ($0.20) earnings per share. The business’s revenue was up 89.9% on a year-over-year basis. Analysts expect that Evolent Health will post ($0.40) earnings per share for the current year.
In related news, COO Thomas Peterson III sold 40,540 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $26.00, for a total value of $1,054,040.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steve Wigginton sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $24.64, for a total transaction of $147,840.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,840 shares of company stock valued at $1,588,679. 8.79% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Evolent Health (EVH) Given Daily Media Sentiment Score of 0.21” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/11/evolent-health-evh-given-daily-media-sentiment-score-of-0-21.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Stock Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related stocks with our FREE daily email newsletter.